Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
- Biofrontera secured $16 million in funding through a financing deal.
- The company can now focus on R&D activities and commercial growth.
- The financing includes a combination of preferred stock and warrants.
- Roth Capital Partners was the exclusive agent for the private placement.
- Funds will be utilized for general business operations and product development.
- Biofrontera's lead product, Ameluz, is approved for treating actinic keratosis.
- The securities issued are part of a private placement under specific regulations.
- None.
Insights
The recent financing completed by Biofrontera Inc. represents a strategic capital infusion that is poised to bolster the company's research and development initiatives and support its commercial growth. The structure of the deal, involving both Series B-1 and Series B-3 Convertible Preferred Stock alongside warrants, is indicative of investor confidence in the company's potential to meet operational and commercial milestones.
The conversion mechanism of the preferred stock into common stock at a fixed price, along with the milestone-based second tranche of financing, is designed to align investor interests with corporate performance. This financing approach can potentially dilute existing shareholders but also provides the company with necessary capital to advance its lead product, Ameluz, for additional indications. The use of proceeds for general business operations and ongoing activities highlights the company's commitment to leveraging the funds to drive growth.
Furthermore, the involvement of healthcare-focused institutional investors and the role of Roth Capital Partners as the exclusive agent underscore the transaction's credibility and the targeted approach towards investors with expertise in the biopharmaceutical sector.
The biopharmaceutical sector is highly competitive and the ability of a company like Biofrontera to secure sizable funding is a testament to its market position and the perceived value of its dermatologic products. The financing news could influence the company's stock performance, as it directly impacts Biofrontera's operational capabilities and its ability to invest in commercial growth.
Investors and market analysts often view such financing rounds as indicators of a company's future prospects. The specifics of the funding, such as the potential for dilution and the milestone-based second tranche, will be closely monitored by the market. The anticipation of meeting operational and commercial milestones by Q2 of 2024 suggests a timeline for evaluating the company's progress and potential stock price implications.
It is important to note the regulatory framework under which this private placement was conducted. The offering was made under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, which exempts certain transactions from the registration requirements. This allows Biofrontera to raise capital efficiently, although it limits the offering to accredited investors.
The commitment to file a resale registration statement with the SEC for the common stock underscores the company's adherence to regulatory obligations and provides a pathway for liquidity to investors. The legal intricacies of such transactions are critical to ensure compliance and to protect the interests of both the company and the investors.
- Company closed financing of
$8.0 million with an additional$8.0 million second tranche tied to milestones for aggregate proceeds of$16 million gross priced at market per Nasdaq rules - Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial growth
WOBURN, MA / ACCESSWIRE / February 23, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that it has closed on a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors as of February 22, 2024. Pursuant to the securities purchase agreements, the Company issued to the purchasers (a) an aggregate
Shares of Series B-1 were issued at a price of
Biofrontera received
The Company intends to use the upfront net proceeds from the private placement to fund the Company's general business operations and ongoing activities related to expediting the development and approval of additional indications for the Company's lead product Ameluz. The product is currently approved in conjunction with the BF-RhodoLED lamp series for the treatment of mild to moderate actinic keratosis on the face and scalp (AK).
The securities to be issued in connection with the private placement described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act of 1933 and such applicable state securities laws. The Company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission (SEC), for purposes of registering the resale of the common stock issued or issuable in connection with the private placement.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
For further information, please see the Company's current report on Form 8-K to be filed with the SEC following the closing of the transaction.
About Actinic Keratosis
Actinic keratosis (AK) is the most common pre-cancerous skin lesion caused by chronic sun exposure that may, if left untreated, develop into life-threatening skin cancer called squamous cell carcinoma. AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or the back of the hands. In 2020 approximately 58 million people in the US were affected by AK and 13 million AK treatments were performed.3
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the closing of the described private placement of securities . We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF- RhodoLED® is consistent with the Company's expectations; the Company's ability to comply with public company requirements; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contact:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on accesswire.com
FAQ
What was the total funding amount secured by Biofrontera Inc. through the financing deal?
Who facilitated the private placement for Biofrontera Inc.?
What will the funds be used for by Biofrontera Inc.?
Which product of Biofrontera Inc. is currently approved for treating actinic keratosis?
Under what regulations were the securities issued in the private placement?
